FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

May 30, 2018
Source URL: https://www.novartis.com/us-en/news/media-releases/fda-expedites-review-novartis-drug-promacta-first-line-severe-aplastic-anemia-saa-0

List of links present in page
  1. https://www.novartis.com/us-en/us-en/news/media-releases/fda-expedites-review-novartis-drug-promacta-first-line-severe-aplastic-anemia-saa-0